N/A
N=12,760
Increasing Influenza and Tdap Vaccination of Pregnant Women
Immunization; Infection · Pregnancy Related
Bottom Line
View on ClinicalTrials.gov: NCT04444518 ↗Enrolled (actual)
12,760
Serious AEs
—
Results posted
Jan 2025
Primary outcome: Primary: Rate of Influenza Vaccination — 2382; 2496 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- VAX-MOM Intervention (Behavioral); Standard of Care (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- University of Rochester
- Primary completion
- Jun 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Influenza Vaccination |
2382; 2496 | — |
| PRIMARY Rate of Tdap Vaccination |
4532; 5452 | — |
Summary
Pregnant women who get influenza are more likely than non-pregnant women to have serious complications, including hospitalizations, death, preterm labor and premature birth. Pertussis can cause hospitalization or death for newborns. However, influenza and Tdap vaccination rates for pregnant women are low nationally. In this study, the investigators will perform a randomized controlled trial aimed at practice change in obstetricians' offices, with an overall goal of reducing morbidity and mortality from influenza and pertussis infections.
Eligibility Criteria
Inclusion Criteria
Patients
- Sex is female
- Pregnant
- identified as being eligible for influenza or Tdap vaccine
Providers
- any provider, nurse or staff associated with the participating sites
Exclusion Criteria
Patients
- none
Providers
- none
Data sourced from ClinicalTrials.gov (NCT04444518). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.